Replication of the GRADE Diabetes Trial in Healthcare Claims Data

Diabetes Clinical Trial

Official title:

Replication of the GRADE Diabetes Trial in Healthcare Claims Data

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05099198
• Other study ID #: 2018P002966-DUP-GRADE
• Status: Completed
• Start date: September 1, 2018
• Est. completion date: August 1, 2021

Study information

• Verified date: July 2023
• Source: Brigham and Women's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Description:

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6403
• Est. completion date: August 1, 2021
• Est. primary completion date: August 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Age greater or equal than 30: days [0,0]

• Diagnosis of Type 2 Diabetes: days [- All Data, 0]

• 2+ recorded HbA1c levels: days [-365,0]

• Metformin use: days [-30, 0]

Exclusion Criteria:

• Type 1 or Secondary DM: days [-All Data, 0]

• Previous organ transplant: days [-All Data, 0]

• HIV/AIDS: days [-All Data, 0]

• History of bariatric surgery: days [-All Data, 0]

• Congestive heart failure: days [-All Data, 0]

• NYHA >=3: days [-All Data, 0]

• Pancreatitis: days [-All Data, 0]

• Medullary thyroid cancer/MEN-2: days [-All Data, 0]

• History of MI: days [-365, 0]

• Stroke: days [-365, 0]

• Coronary Revascularization: days [-365, 0]

• PTCA/Stenting/CABG: days [-365, 0]

• Trans myocardial revascularization: days [-365, 0]

• Carotid bypass: days [-365, 0]

• Cerebrovascular revascularization: days [-365, 0]

• PVD: days [-365, 0]

• CCI >=10: days [-365, 0]

• History of cancer, other than non-melanoma skin cancer: days [-1,825, 0]

• Treatment of metformin more than 10 years: days [-3,650, 0]

• Treatment with any diabetes drug other than metformin; PCOS; symptomatic hyperglycemia; pregnancy; gestational diabetes: days [-180, 0]

• History of hemolytic anemia; history of severe liver disease; current alcoholism; chronic transfusion requirement; ESRD: days [-180, 0]

• Oral, IV, or IM cortisone, hydrocortisone, prednisone, methylprednisone, or dexamethasone: days [-90, 0]

• Treatment with atypical antipsychotics, language barriers, nursing home, or missing age or gender: days {-180, 0]

• Hospitalization with length of stay >3 days: days [-30, 0]

Related Conditions & MeSH terms

• Diabetes
• Diabetes Mellitus

Intervention

Drug:
• Sitagliptin
Sitagliptin dispensing claim is used as the reference
• Glimepiride
Glimepiride dispensing claim is used as the reference

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time until failure to maintain metabolic control	Lab based algorithm: time until failure to maintain metabolic control (HbA1c level >= 7.0% or 53 mmol/mol)	Through censoring or study completion, up to 765 days after cohort entry
Secondary	Time until a severe hypoglycemic episode	Claims based algorithm: time until a severe hypoglycemic episode	Through censoring or study completion, up to 765 day after cohort entry
Secondary	HbA1C change from baseline	Lab based algorithm: HbA1C change from baseline	Through censoring or study completion, up to 765 days after cohort entry